Description

3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[2,2,2-trifluoro-1-(trifluoroMethyl)-1-[[3,3,3-trifluoro-1-oxo-2-(trifluoroMethyl)propyl]aMino]ethyl]-1-piperazinyl]- is a high-purity, advanced pharmaceutical intermediate of significant commercial and research importance. Its complex, multi-fluorinated structure makes it a critical building block in the synthesis of novel fluoroquinolone antibiotics, which are essential in combating resistant bacterial strains. This compound is primarily sought by pharmaceutical R&D laboratories, API (Active Pharmaceutical Ingredient) manufacturers, and fine chemical suppliers serving the global healthcare sector.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of next-generation fluoroquinolone antibacterial agents.
• Active Pharmaceutical Ingredient (API) Development: Used in research and process development for novel antibiotic candidates targeting multi-drug resistant bacteria.
• Chemical Synthesis & Process Optimization: Serves as a model compound for developing and scaling up complex fluorination and heterocyclic coupling reactions.
• Biomedical Research: Employed in academic and industrial research to study structure-activity relationships (SAR) of quinolone-based therapeutics.
• Reference Standard: Used as a high-purity analytical standard for quality control and regulatory submissions in pharmaceutical manufacturing.

Basic Information

Product Name	3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-[2,2,2-trifluoro-1-(trifluoroMethyl)-1-[[3,3,3-trifluoro-1-oxo-2-(trifluoroMethyl)propyl]aMino]ethyl]-1-piperazinyl]-
CAS No.	524704-73-2
Molecular Formula	C24H20F13N3O4
Molecular Weight	637.42 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-{2,2,2-trifluoro-1-(trifluoromethyl)-1-[(3,3,3-trifluoro-1-oxo-2-(trifluoromethyl)propyl)amino]ethyl}-1-piperazinyl)-3-quinolinecarboxylic acid; WCK 771 Intermediate; Nemonoxacin Intermediate; ABT-492 Intermediate; Advanced Fluoroquinolone Intermediate; 7-(4-(1-(Amino(3,3,3-trifluoro-1-oxo-2-(trifluoromethyl)propyl)(trifluoromethyl)methyl)-2,2,2-trifluoroethyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict cGMP (current Good Manufacturing Practice) guidelines to ensure batch-to-batch consistency and traceability. Every lot undergoes comprehensive analytical characterization using HPLC, NMR, and Mass Spectrometry to confirm identity and purity. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting critical quality attributes. We support our partners in meeting the stringent documentation requirements for Drug Master File (DMF) submissions and regulatory audits.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and must be kept under an inert atmosphere (e.g., nitrogen or argon) in its original packaging to prevent degradation. Keep away from heat and incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Conforms to reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.